We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Artificial Intelligence Test Determines Risk of Bowel Cancer Recurrence After Surgery

By LabMedica International staff writers
Posted on 02 Aug 2024

Bowel cancer, commonly referred to as colorectal cancer, can develop anywhere in the large bowel, including the colon and rectum. More...

It ranks among the most prevalent cancers globally, with 1.9 million new cases recorded in 2020. The current protocols for determining the need for chemotherapy for patients with early-stage bowel cancer are not consistently reliable. As a result, some patients receive chemotherapy unnecessarily, while others who might benefit from it do not receive it and may face cancer recurrence. This decision is particularly challenging for stage II colon cancer, where the risk of recurrence post-surgery is generally lower. Now, a new artificial intelligence (AI) test can predict the risk of recurrence in bowel cancers, potentially helping patients avoid unnecessary chemotherapy. This test employs an AI algorithm to measure the concentration of immune cells known as CD3 in tumors at the early stages of bowel cancer.

Previous studies have indicated that bowel and rectal tumors with a higher presence of CD3 immune cells have a reduced likelihood of recurrence after surgical removal. This is attributed to the ability of CD3 cells to combat cancer, aiding the body's response to the disease. In the latest study by researchers at the University of Leeds (West Yorkshire, UK), the CD3 Score test effectively identified which stage II cancers were more prone to recurrence within five years post-surgery. This information could aid clinicians in determining the need for additional treatments, such as chemotherapy. The study analyzed tissue samples from 868 bowel tumors classified as stage II and III to quantify the CD3 cells present within the tumors.

The AI algorithm developed by the research team calculated a 'CD3 Score' based on the distribution of CD3 cells throughout the tumor. Tumors assigned a high-risk CD3 Score displayed fewer immune cells, whereas those with a low-risk score exhibited a higher number of immune cells. Tumors categorized with a high-risk CD3 Score were three times more likely to recur within five years of surgery compared to those with a low-risk score. Although chemotherapy reduced recurrence rates in both groups, the study further revealed that patients with fewer immune cells gained the most from chemotherapy. These findings, published in the Journal of Clinical Oncology, could assist doctors in making informed decisions about administering chemotherapy following bowel cancer surgery.

“This has the potential to be the most important test patients with early-stage bowel cancer ask for. It’s fast, accurate and simple, and we hope it will make conversations about chemotherapy after surgery much more straightforward for patients and their doctors,” said lead author Dr. Christopher Williams, Cancer Research UK Clinical Trials Research Fellow in the University of Leeds’ School of Medicine.

Related Links:
University of Leeds


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid Meter
PA-16
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: This image shows a second-generation version of the device that can also measure cell morphology (Photo courtesy of MIT)

Rapid Cell Density Measurement Technique to Help Predict Immunotherapy Response

The density of a cell provides valuable insights into its condition. As cells go through processes such as proliferation, differentiation, or cell death, they may gain or lose water and other molecules,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.